- Home
- TFPM vs ZLAB Comparison
TFPM vs ZLAB Comparison
Compare TFPM & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFPM
- ZLAB
- Stock Information
- Founded
- TFPM 2016
- ZLAB 2013
- Country
- TFPM Canada
- ZLAB China
- Employees
- TFPM N/A
- ZLAB N/A
- Industry
- TFPM Precious Metals
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- TFPM Industrials
- ZLAB Health Care
- Exchange
- TFPM Nasdaq
- ZLAB Nasdaq
- Market Cap
- TFPM 3.3B
- ZLAB 3.0B
- IPO Year
- TFPM N/A
- ZLAB 2017
- Fundamental
- Price
- TFPM $15.39
- ZLAB $26.72
- Analyst Decision
- TFPM Strong Buy
- ZLAB Strong Buy
- Analyst Count
- TFPM 4
- ZLAB 3
- Target Price
- TFPM $20.50
- ZLAB $55.00
- AVG Volume (30 Days)
- TFPM 321.6K
- ZLAB 761.7K
- Earning Date
- TFPM 01-01-0001
- ZLAB 11-12-2024
- Dividend Yield
- TFPM 1.45%
- ZLAB N/A
- EPS Growth
- TFPM N/A
- ZLAB N/A
- EPS
- TFPM N/A
- ZLAB N/A
- Revenue
- TFPM $246,517,000.00
- ZLAB $355,748,000.00
- Revenue This Year
- TFPM $33.62
- ZLAB $48.50
- Revenue Next Year
- TFPM $11.43
- ZLAB $47.37
- P/E Ratio
- TFPM N/A
- ZLAB N/A
- Revenue Growth
- TFPM 25.66
- ZLAB 35.01
- 52 Week Low
- TFPM $11.75
- ZLAB $13.48
- 52 Week High
- TFPM $18.88
- ZLAB $36.60
- Technical
- Relative Strength Index (RSI)
- TFPM 34.49
- ZLAB 46.04
- Support Level
- TFPM $15.81
- ZLAB $25.71
- Resistance Level
- TFPM $17.01
- ZLAB $27.49
- Average True Range (ATR)
- TFPM 0.40
- ZLAB 1.07
- MACD
- TFPM -0.12
- ZLAB -0.17
- Stochastic Oscillator
- TFPM 11.47
- ZLAB 21.54
About TFPM Triple Flag Precious Metals Corp.
Triple Flag Precious Metals Corp is a precious-metals-focused streaming and royalty company. Its revenues are largely generated from a diversified portfolio of properties in Australia, Canada, Colombia, Cote d'Ivoire, Honduras, Mexico, Mongolia, Peru, South Africa, and the United States.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.